Santa Monica, CA, United States of America

Lin Jiang

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Los Angeles, CA (US) (2018 - 2019)
  • Santa Monica, CA (US) (2020 - 2022)

Company Filing History:


Years Active: 2018-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Lin Jiang: Innovator in Peptide Inhibitors

Introduction

Lin Jiang is a prominent inventor based in Santa Monica, CA, known for his significant contributions to the field of peptide inhibitors. With a total of four patents to his name, Jiang's work focuses on addressing critical health issues related to α-synuclein aggregation, which is linked to neurodegenerative diseases.

Latest Patents

Jiang's latest patents include innovative approaches to inhibit α-synuclein aggregation. One of his notable inventions is a structure-based peptide inhibitor that binds to α-synuclein molecules, effectively inhibiting their amyloidogenic aggregation and cytotoxicity. This invention has potential applications in treating conditions such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy (MSA). The methods described in his patents outline how these inhibitory peptides can be utilized to combat diseases mediated by α-synuclein.

Career Highlights

Lin Jiang is affiliated with the University of California, where he continues to advance research in the field of peptide inhibitors. His work has garnered attention for its potential to revolutionize treatment options for neurodegenerative diseases.

Collaborations

Jiang collaborates with esteemed colleagues, including David S. Eisenberg and Alice Soragni, who contribute to the research and development of his innovative ideas.

Conclusion

Lin Jiang's contributions to the field of peptide inhibitors highlight his commitment to addressing significant health challenges. His innovative patents pave the way for potential breakthroughs in the treatment of neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…